Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The company’s pioneering research aims to develop and commercialize cancer therapeutics that target the DNA damage response (DDR) pathways. Aprea's lead product candidate, ATRN-119, is a macrocyclic ATR inhibitor designed for treating solid tumors with DDR-related gene mutations. This inhibitor is currently in a Phase 1/2a clinical trial and has shown promising preliminary data, being well tolerated with no dose-limiting toxicities.
Another key candidate, APR-1051, is a highly selective WEE1 kinase inhibitor. The company recently received FDA clearance for an Investigational New Drug (IND) application for APR-1051, enabling the initiation of a Phase 1 clinical trial aimed at treating cancers that overexpress Cyclin E, including ovarian and breast cancers. Preclinical studies have demonstrated APR-1051's potential low toxicity and high selectivity, making it a candidate for best-in-class treatment.
Aprea’s commitment to advancing precision oncology is underscored by recent financial results and corporate developments. For instance, as of March 31, 2024, the company reported $32.4 million in cash and cash equivalents. Notably, Aprea has secured a private placement financing of up to $34 million to support its ongoing and upcoming clinical trials. Furthermore, Aprea’s strong leadership team, including newly appointed Chief Medical Officer Dr. Nadeem Q. Mirza, continues to drive the company’s strategic initiatives.
Recent achievements include the presentation of promising preclinical and clinical data at major conferences such as the AACR Annual Meeting. These presentations highlighted the potential of ATRN-119 and APR-1051 in treating cancers with specific genetic mutations, reinforcing Aprea’s potential to fill significant unmet medical needs in oncology.
For more detailed information about Aprea Therapeutics and its innovative approaches to cancer treatment, please visit their website at www.aprea.com.
Aprea Therapeutics (Nasdaq: APRE) reports Q1 2021 financial results, revealing a net loss of $9.7 million or $0.46 per share. The company reported a decrease in R&D expenses to $6.8 million, down from $9.1 million a year earlier. Aprea continues development of eprenetapopt and APR-548 across several clinical trials. While a Phase 3 trial did not meet primary efficacy endpoints, interim analyses from other trials indicated promising rates of relapse-free survival and overall survival. The company expects its cash reserves will sustain operations into 2023.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a virtual R&D Day on April 22, 2021, at 1:00 p.m. ET. This event will feature presentations by CEO Christian S. Schade and CMO Eyal C. Attar, focusing on the results of a completed Phase 3 trial for MDS and ongoing research. Register for the event on Aprea's website, where a replay will be available afterward. Aprea specializes in cancer therapies that reactivate the p53 protein, with its lead candidate, eprenetapopt (APR-246), showing promise in treating various cancers.
Aprea Therapeutics (Nasdaq: APRE) announced the FDA's Orphan Drug designation for eprenetapopt, aimed at treating acute myeloid leukemia (AML). This follows the prior Fast Track designation granted in November 2020. Orphan Drug designation offers several benefits, including a seven-year market exclusivity post-approval and FDA support in clinical trial design. Eprenetapopt is being developed to reactivate the mutant p53 protein in cancer cells, with additional designations for other conditions, including myelodysplastic syndromes and ovarian cancer.
Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2020, highlighting a net loss of $15.4 million, or $0.73 per share. Their pivotal Phase 3 trial for eprenetapopt missed its primary endpoint for complete remission but showed a 53% improvement versus control. The Company has multiple ongoing trials for eprenetapopt and APR-548, their next-generation p53 reactivator, and expects to present additional findings in Q2 2021. As of December 31, 2020, cash and cash equivalents were $89 million, with anticipated cash burn of $30-35 million for 2021.
Aprea Therapeutics (Nasdaq: APRE), a biopharmaceutical company, is set to present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. ET. The presentation will provide insights into the company's innovative cancer therapeutics aimed at reactivating the p53 tumor suppressor protein. A live webcast will be available on the company's website. Aprea's lead product candidate, eprenetapopt (APR-246), is in clinical development and has received various FDA designations for myelodysplastic syndromes and acute myeloid leukemia.
Aprea Therapeutics (Nasdaq: APRE) announced the results of its Phase 3 clinical trial evaluating eprenetapopt with azacitidine (AZA) for TP53 mutant myelodysplastic syndromes (MDS). The trial did not achieve its primary endpoint of complete remission (CR) rate, with 33.3% CR in the eprenetapopt plus AZA arm compared to 22.4% in the AZA alone arm (P = 0.13). Despite this, secondary endpoints showed some favor toward the experimental arm. The combination was well-tolerated, and further analyses will be conducted as patient data matures.
Aprea Therapeutics (Nasdaq: APRE) announced that the FDA granted Fast Track designation for eprenetapopt, aimed at treating patients with TP53 mutant acute myeloid leukemia (AML). This designation helps expedite the development and review process for drugs addressing serious conditions. Aprea previously obtained Breakthrough Therapy and Orphan Drug designations for eprenetapopt for myelodysplastic syndromes (MDS). The company is actively enrolling patients in clinical trials for eprenetapopt combined with azacitidine and venetoclax, with promising initial data expected in 2021.
Aprea Therapeutics (Nasdaq: APRE), a biopharmaceutical company focused on cancer therapeutics, will have its CEO Christian S. Schade and CMO Eyal Attar participate in a fireside chat at the virtual Piper Sandler Healthcare Conference from December 1-3, 2020. The pre-recorded chat will be available for limited viewing starting November 23, 2020, on the company's investors website. Aprea is known for developing drugs that reactivate the mutant tumor suppressor protein, p53, with its lead product candidate, eprenetapopt (APR-246), targeting hematologic malignancies.
Aprea Therapeutics (Nasdaq: APRE) reported its Q3 2020 financial results and business updates, focusing on its lead product candidate, eprenetapopt. The company has completed enrollment in pivotal Phase 3 trials for TP53 mutant MDS with azacitidine and is enhancing its clinical pipeline in AML and solid tumors. As of September 30, 2020, Aprea had $101.1 million in cash, down from $130.1 million at 2019 year-end, and anticipates a cash burn of $35-40 million for 2020. The net loss for Q3 2020 was $12.3 million, or $0.58 per share, compared to $6.2 million in Q3 2019.
Aprea Therapeutics (Nasdaq: APRE) hosted a virtual R&D Day Webinar on October 30, 2020, featuring discussions by experts in hematology regarding clinical therapies for TP53 mutant MDS/AML patients. The agenda included a review of Aprea's Phase 3 clinical program and commercial strategies. Aprea's lead candidate, eprenetapopt, targets mutant tumor suppressor protein p53 and has received multiple FDA designations for MDS. The company is developing APR-548 as a next-generation agent with a planned Phase 1 trial. For more information, visit Aprea's website.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
What is Aprea Therapeutics' main focus?
What are Aprea Therapeutics' lead product candidates?
What is the current status of ATRN-119?
What recent achievement is related to APR-1051?
How is Aprea Therapeutics funded for its clinical trials?
Who is the newly appointed Chief Medical Officer at Aprea Therapeutics?
What significant events did Aprea participate in recently?
What are some unique attributes of ATRN-119?
What is Aprea's approach to addressing unmet medical needs in oncology?
Where can I find more information about Aprea Therapeutics?
